Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 17/20 | 0.49 |
| ▸ | DHFR | P00374 | 4/20 | 0.49 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.49 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.49 |
| ▸ | GART | P22102 | 1/20 | 0.49 |
| ▸ | ATIC | P31939 | 1/20 | 0.49 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.49 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.49 |
| ▸ | FRK | P42685 | 1/20 | 0.49 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.49 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28417050 | 0.93 | TYMS (0.45) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL1238667 | 0.86 | TYMS (0.46) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL28422384 | 0.85 | TYMS (0.43) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL18780148 | 0.82 | TYMS (0.39) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL17200119 | 0.82 | TYMS (0.39) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL10324414 | 0.82 | GART (0.65) | TYMSDHFRFOLR2FOLR1GART | |
| Pemetrexed SCHEMBL2549428 | 0.81 | GART (0.77) | TYMSDHFRFOLR2FOLR1GART | |
| Pemetrexed SCHEMBL7969 | 0.81 | GART (0.77) | TYMSDHFRFOLR2FOLR1GART | |
| Pemetrexed SCHEMBL7968 | 0.81 | GART (0.77) | TYMSDHFRFOLR2FOLR1GART | |
| Pemetrexed SCHEMBL6034765 | 0.81 | GART (0.77) | TYMSDHFRFOLR2FOLR1GART |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111333658-A | Preparation method of pemetrexed disodium hydrate | 贵州联科中贝制药科技有限公司 | 2020-06-26 | — | — | CN | claimed |
| EP-2675808-A2 | PROCESS FOR PEMETREXED DISODIUM | Hetero Research Foundation (IN) | 2013-12-25 | — | — | EP | claimed |
| US-20130165654-A1 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES, INC. (US) | 2013-06-27 | — | — | US | claimed |
| WO-2012111027-A2 | PROCESS FOR PEMETREXED DISODIUM | HETERO RESEARCH FOUNDATION (IN) | 2012-08-23 | — | — | WO | claimed |
| EP-2464650-A2 | PROCESSES FOR PREPARING PEMETREXED | Dr. Reddy's Laboratories, Ltd. (IN) | 2012-06-20 | — | — | EP | claimed |
| US-20110124861-A1 | Process for Preparing Pemetrexed Disodium and Its Intermediate, 4-(4-Carbomethoxyphenyl) Butanal | SHANGHAI CDYMAX PHARMACEUTICALS CO., LTD (CN) | 2011-05-26 | — | — | US | claimed |
| EP-2301909-A1 | PROCESSES FOR PREPARING PEMETREXED DISODIUM AND ITS INTERMEDIATE,4-(4-CARBOMETHOXYPHENYL)BUTANAL | Shanghai Cdymax Pharmaceuticals Co., Ltd (CN) | 2011-03-30 | — | — | EP | claimed |
| WO-2011019986-A2 | PROCESSES FOR PREPARING PEMETREXED | DR. REDDY'S LABORATORIES LTD. (IN) | 2011-02-17 | — | — | WO | claimed |
| CN-120424080-A | Confession is banked up with earth and is met with earth preparation of trastuffer disodium preparation method of used intermediate | 湖南赛隆药业(长沙)有限公司 | 2025-08-05 | — | — | CN | disclosed |
| CN-118619955-A | Preparation method and application of pemetrexed key intermediate | 江苏海洋大学 | 2024-09-10 | — | — | CN | disclosed |
| US-20240165016-A1 | INTRAVENOUS INFUSION DOSAGE FORM FOR PEMETREXED | SUN PHARMACEUTICAL INDUSTRIES LTD (IN) | 2024-05-23 | — | — | US | disclosed |
| CN-116768901-A | Preparation method of pemetrexed disodium | 贵州阜康仁制药有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116768901-A | Preparation method of pemetrexed disodium | 贵州阜康仁制药有限公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-3804686-B1 | INTRAVENOUS INFUSION DOSAGE FORM FOR PEMETREXED | SUN PHARMACEUTICAL IND LTD (IN) | 2023-08-30 | — | — | EP | disclosed |
| EP-0905128-B1 | Processes and intermediates useful to make antifolates | LILLY CO ELI (US) | 2002-02-20 | — | — | EP | disclosed |
| US-20010011142-A1 | Processes and intermediates useful to make antifolates | KJELL DOUGLAS PATTON (US) | 2001-08-02 | — | — | US | disclosed |
| US-6262262-B1 | PRODUCING 4-(2-(2-AMINO-4,7-DIHYDRO-4-OXO-1H-PYRROLO(2, 3-D)PYRIMIDIN-5-YL)ETHYL)BENZOIC ACID DERIVATIVE BY REACTING HYDROXY-4-(4-CARBOMETHOXYPHENYL)BUTANESULFONIC ACID METAL SALT WITH TRIALKYLSILYL HALIDE; REACTING WITH | ELI LILLY AND COMPANY | 2001-07-17 | — | — | US | disclosed |
| US-6090168-A | Processes and intermediates useful to make antifolates | ELI LILLY AND COMPANY (US) | 2000-07-18 | — | — | US | disclosed |
| US-6013828-A | Processes and intermediates useful to make antifolates | ELI LILLY AND COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| EP-0905128-A1 | Processes and intermediates useful to make antifolates | ELI LILLY AND COMPANY (US) | 1999-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124861-A1 | Process for Preparing Pemetrexed Disodium and Its Intermediate, 4-(4-Carbomethoxyphenyl) Butanal | BPGM, PCNA, BRD1 | TYMS 11/4885DHFR 64/4885FOLR2 1413/4885 |
| US-20240165016-A1 | INTRAVENOUS INFUSION DOSAGE FORM FOR PEMETREXED | SLC19A1, FOLR2, SLC29A1 | TYMS 34/4885DHFR 31/4885FOLR2 2/4885 |
| US-20130165654-A1 | PROCESSES FOR PREPARING PEMETREXED | TYMP, TYMS, DPYD | TYMS 2/4885DHFR 10/4885FOLR2 74/4885 |
| US-20010011142-A1 | Processes and intermediates useful to make antifolates | DPYD, DHFR, MPST | TYMS 10/4885DHFR 2/4885FOLR2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.